Glenmark Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Glenmark Pharmaceuticals has a total shareholder equity of ₹97.4B and total debt of ₹51.8B, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are ₹200.1B and ₹102.7B respectively. Glenmark Pharmaceuticals's EBIT is ₹11.2B making its interest coverage ratio 2.5. It has cash and short-term investments of ₹11.2B.
Key information
53.2%
Debt to equity ratio
₹51.82b
Debt
| Interest coverage ratio | 2.5x |
| Cash | ₹11.24b |
| Equity | ₹97.36b |
| Total liabilities | ₹102.71b |
| Total assets | ₹200.06b |
Recent financial health updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Recent updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10Increases to Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Might Cool off for now
Sep 17Glenmark Pharmaceuticals' (NSE:GLENMARK) Dividend Will Be ₹2.50
Aug 27Financial Position Analysis
Short Term Liabilities: GLENMARK's short term assets (₹112.7B) exceed its short term liabilities (₹58.4B).
Long Term Liabilities: GLENMARK's short term assets (₹112.7B) exceed its long term liabilities (₹44.3B).
Debt to Equity History and Analysis
Debt Level: GLENMARK's net debt to equity ratio (41.7%) is considered high.
Reducing Debt: GLENMARK's debt to equity ratio has reduced from 75% to 53.2% over the past 5 years.
Debt Coverage: GLENMARK's debt is not well covered by operating cash flow (13.9%).
Interest Coverage: GLENMARK's interest payments on its debt are not well covered by EBIT (2.5x coverage).